CryoLife, Inc. (NYSE: CRY), a biomaterials, medical device and tissue processing company, has announced that positive mid-term performance documents on the CryoValve(R) SG decellularized pulmonary human heart valve were presented on June 28th at the 34th Annual Western Thoracic Surgical organization...

deCODE genetics (Nasdaq: DCGN) announced positive topline results from its latest clinical pharmacology study of DG041, the company’s first-in-class antagonist of the EP3 receptor for prostaglandin E2, developed as a next-generation oral anti-platelet therapy for preventing arterial thrombosis...

Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, announced a status update for its continuing Phase I/IIa Chemophase(R) clinical trial in the treatment of superficial bladder cancer. Based on the...

Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, announced the publication of input from a phase 1 dose escalation study evaluating the effects of IL-7 therapy on human lymphocytes in subjects with non-hematologic, non-lymphoid...

The American Society of Breast Disease announces the creation of the Mary Kay Ash Advanced Training Program in Oncoplastic Breast Surgery. The Addison-based Mary Kay Ash Charitable Foundation – a main philanthropy in the field of cancers affecting women – has approved a two-year $225,000...

With millions of sufferers out there, all with varying degrees of glucose intolerance, don’t panic you are not alone. The real problem with type 2 diabetes is high blood sugar, by duration it can and will, cause a multitude of problems. So as the title states, you number one precedence in reversing...